FDA Warns Companies to Stop Selling Potentially Dangerous, Unapproved Eye Drops

FDA Warns Companies to, Stop Selling Potentially Dangerous, , Unapproved Eye Drops.
Gizmodo reports that the United States Food and
Drug Administration (FDA) has warned several companies
to stop selling unapproved eye drop products.
On September 12, the FDA announced that it had
issued warning letters to eight companies
regarding the potentially dangerous products.
The companies, including major retail chains CVS and
Walgreens, have allegedly committed a number of
violations by marketing or manufacturing these products.
The companies, including major retail chains CVS and
Walgreens, have allegedly committed a number of
violations by marketing or manufacturing these products.
The companies, including major retail chains CVS and
Walgreens, have allegedly committed a number of
violations by marketing or manufacturing these products.
The FDA has also expressed concerns over silver
compounds found in some of the products, which can
turn people's skin or eyes blue with long-term use.
According to the FDA, some of the eye drop products
were allegedly manufactured at facilities that have
failed to meet standard safety and quality guidelines.
The FDA is particularly concerned that these
illegally marketed, unapproved ophthalmic
drug products pose a heightened
risk of harm to users because drugs
applied to the eyes bypass some
of the body’s natural defenses, Food and Drug Administration, via statement.
The FDA is particularly concerned that these
illegally marketed, unapproved ophthalmic
drug products pose a heightened
risk of harm to users because drugs
applied to the eyes bypass some
of the body’s natural defenses, Food and Drug Administration, via statement.
Gizmodo reports that the companies
have 15 days to respond with their
plans to correct the alleged violations.
If the companies fail to respond, the FDA could
take further action to either seize or stop the
manufacturing of the products in question.
When we identify illegally marketed,
unapproved drugs and lapses in drug
quality that pose potential risks,
the FDA works to notify the
companies involved of the violations, Jill Furman, Director of the Office of Compliance for the FDA’s
Center for Drug Evaluation and Research, via Gizmodo.
We will continue to investigate potentially
harmful eye products and work to ensure
violative products stay off store shelves
so that consumers can continue taking
the medicines they need without concern, Jill Furman, Director of the Office of Compliance for the FDA’s
Center for Drug Evaluation and Research, via Gizmodo.
We will continue to investigate potentially
harmful eye products and work to ensure
violative products stay off store shelves
so that consumers can continue taking
the medicines they need without concern, Jill Furman, Director of the Office of Compliance for the FDA’s
Center for Drug Evaluation and Research, via Gizmodo